MedTech News & Analysis
2 articles
Market Mood
Becton Dickinson (BDX) Price Target Trimmed to $159 by Piper Sandler
Piper Sandler has reduced the price target for Becton, Dickinson and Company (BDX) from $170 to $159 while maintaining a Neutral rating. This adjustment was made on April 17, 2026, to align with management's revenue growth guidance. Additionally, RBC Capital Markets lowered its price target for BDX to $175 from $195, citing stable fundamentals in the MedTech sector. Both firms note that current sentiment around BDX may create investment opportunities, but they expect the stock to remain range-bound due to a lack of clear catalysts.
Read More
Medtech Industry Growth Driven by Infrastructure Investments Over Next Decade
The medtech sector is expected to see significant growth over the next decade, largely fueled by increased investments in healthcare infrastructure. This shift is crucial as it aligns with trends towards more advanced and accessible medical technologies, reflecting a broader commitment to enhancing patient care. Key data indicates that the industry could witness a compound annual growth rate (CAGR) exceeding 5% during this period. Market analysts suggest that these foundational developments will not only bolster medtech stocks but also trigger a ripple effect throughout related sectors.
Read More